logo
Respiratory Training Shows Modest Benefits in ALS

Respiratory Training Shows Modest Benefits in ALS

Medscape30-06-2025
TOPLINE:
Respiratory muscle training moderately improved lung function, especially respiratory muscle strength, in patients with amyotrophic lateral sclerosis (ALS) compared with no intervention or sham training.
METHODOLOGY:
Researchers conducted a meta-analysis to assess the effect of respiratory muscle training on lung function and respiratory muscle strength in patients with ALS.
They gathered data from five randomized controlled trials including 170 patients with ALS (mean age range, 53-63 years; 58.8%-69.2% men), majority of whom had spinal onset of the disease (72.9%-84.6%).
Researchers assessed the role of standalone respiratory muscle training and compared it with control conditions — physical exercise, usual care, or no intervention — to gauge its unique impact.
The outcomes included assessments of lung function, respiratory muscle strength, survival, functional capacity, and adverse events.
TAKEAWAY:
According to a meta-analysis of three trials, maximum expiratory pressure was superior in the group that underwent respiratory muscle training compared with control conditions (standardized mean difference [SMD], 19.53; P = .02).
Similarly, respiratory muscle training significantly improved the maximum inspiratory pressure compared with control conditions (SMD, 13.96; P = .010).
A meta-analysis of four trials found no significant difference in the forced vital capacity between the groups (SMD, 0.90; P = .14).
No studies reported serious adverse effects, supporting respiratory muscle training as a safe intervention for patients with ALS.
IN PRACTICE:
'RMT [respiratory muscle training] shows potential as an adjuvant intervention for patients with ALS,' the authors wrote.
SOURCE:
This study was led by María Jesús Benzo-Iglesias, Health Research Centre, Humanidades-498 Research Group, University of Almería, Almería, Spain. It was published online on June 09, 2025, in Therapeutic Advances in Respiratory Disease.
LIMITATIONS:
This study had a small sample size, which limited the generalizability of the findings. It comprised only five trials, which may have affected the findings' robustness and restricted the ability to perform sensitivity analyses. The wide CIs in the heterogeneity analysis indicated substantial heterogeneity.
DISCLOSURES:
This study did not receive any funding. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound
Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

Yahoo

time7 minutes ago

  • Yahoo

Analysis-Wall Street sees new obesity pills as priced near Wegovy and Zepbound

By Maggie Fick and Bhanvi Satija SEATTLE (Reuters) -U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with their weight-loss injections, analysts and investors say, in a departure from the usual practice of charging more for new medicines despite pressure to cut prices. Neither drugmaker has disclosed pricing plans for their new daily oral medications. With regulatory approvals and launches still months away, pricing plans could change. Denmark-based Novo expects approval later this year and to launch soon after, while Indianapolis-based Lilly expects to launch by August 2026. Novo's Wegovy and Lilly's Zepbound, administered as weekly injections, are the only highly effective weight-loss drugs targeting the GLP-1 hormone, and the United States is their biggest market. U.S. list prices are about $1,000 per month or more, with both companies offering a monthly supply for $499 to customers paying cash rather than using health insurance. Both companies have said they developed oral weight-loss drugs to meet patient needs and widen access to the market, mindful that some people are averse to injections. The pills, however, are not more effective than the injections. Lilly said this month its pill orforglipron cut weight by 12.4% after 72 weeks in a trial. That compares with weight loss of 15% for Novo's daily oral semaglutide. Both trail Lilly's injection at up to 21%. UBS analyst Trung Huynh said that will cap Lilly's pricing. The price is "probably going to come on par with the current drugs today or slightly lower," Huynh said. TD Cowen analyst Michael Nedelcovych said he expects Novo's pill to debut near Wegovy's price, citing the precedent of its diabetes pill Rybelsus being priced at parity with injection Ozempic, the diabetes-treatment version of Wegovy. Novo executives told analysts this month they were not in a hurry for discount pricing for the new pill. Oral GLP-1 drugs will fill a niche rather than displace injections, according to analysts. TD Cowen estimates that pills will account for a percentage share of the global obesity drug market in the mid-teens by 2030, which could reach $150 billion by then. GROWING CASH PAY U.S. doctors, patients and insurers are pressing for lower prices to make the weight-loss drugs more affordable for the 40% of Americans who are obese. Typically, drugmakers launch new drugs at higher prices, citing scientific advances. President Donald Trump and lawmakers from both parties have urged the companies to reduce U.S. prices. Novo declined to comment on pricing, pointing to August 6 comments by David Moore, its U.S. operations head, saying that the company may tap customers paying cash directly via its new NovoCare pharmacy, which was launched this year to sell Wegovy outside of insurance. A Lilly spokesperson called it premature to comment on pricing and launch plans for its pill because the company has not yet submitted data for regulatory approval. Peak annual sales forecasts for Lilly's orforglipron fell to as low as $10 billion after its trial data from earlier estimates of up to $30 billion, according to a Reuters review of analyst estimates. HSBC forecasts $15 billion in peak annual sales for Novo's pill, while Barclays expects only $1 billion. MANUFACTURING VOLUME A key question is how much supply will be available at the time of launch. Shortages of injectable GLP-1s in 2023 and 2024 opened the U.S. market to cheaper compounded versions as the manufacturers failed to anticipate the huge demand. "It's all about scale and pricing," said Kevin Gade, portfolio manager at Bahl & Gaynor, which owns Lilly shares. Gade pointed to Novo's manufacturing challenge. The pill form requires about 75 times more active ingredient than the highest-dose Wegovy injection, two analysts told Reuters. Lilly has said it already has $808.5 million in orforglipron inventory for next year's expected launch. Novo has said it will launch its pill without supply constraints after billions of dollars in investment to expand semaglutide production. Despite the high production needs, Novo is unlikely to debut its pill at a higher price than Wegovy, said Karen Andersen, healthcare strategist at Morningstar. "Particularly in the growing cash-pay market, I doubt it can risk a launch at a premium to Wegovy," Andersen added. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Forest Lake Endodontics Welcomes Endodontist Dr. Linda Liu to the Practice
Forest Lake Endodontics Welcomes Endodontist Dr. Linda Liu to the Practice

Yahoo

time7 minutes ago

  • Yahoo

Forest Lake Endodontics Welcomes Endodontist Dr. Linda Liu to the Practice

FOREST LAKE, Minn., Aug. 18, 2025 /PRNewswire/ -- Forest Lake Endodontics in Forest Lake, Minnesota, announced today that endodontist Dr. Linda Liu has joined its team, bringing advanced training in root canal treatment and a strong commitment to patient-centered care. Dr. Liu earned her Bachelor of Science in Microbiology with a minor in Mathematics from the University of Michigan in Ann Arbor. She went on to obtain her Doctor of Dental Surgery degree and complete a General Practice Residency at the University of Toledo. Dr. Liu then specialized in Endodontics at the University of Minnesota, where she also earned her Master's degree. Residing in Blaine with her husband, Philip, an anesthesiology resident at the University of Minnesota, and their goldendoodle, Dr. Liu looks forward to serving patients in the greater Forest Lake community. Outside of her professional life, she enjoys playing the piano, pickleball, traveling to new destinations, and exploring local restaurants. Forest Lake Endodontics has served the Twin Cities metro area for 6 years, specializing in root canal therapy and other advanced endodontic treatments in a welcoming environment. The practice partners closely with referring dentists to provide patients with seamless, high-quality care. "I am honored to join the talented team at Forest Lake Endodontics," said Dr. Liu. "It is incredibly rewarding to relieve patients' discomfort and preserve their natural teeth. I look forward to contributing my skills and working alongside my colleagues to deliver the highest level of care." Forest Lake Endodontics provides the following services: Root canal treatment. Root canal retreatment. Endodontic surgery (apicoectomy). Emergency dental care for traumatic injuries. Advanced diagnostics for tooth pain. External root resorption repairs. About Forest Lake Endodontics Forest Lake Endodontics specializes in advanced endodontic treatments designed to save natural teeth and restore oral health. The practice combines cutting-edge technology with a patient-first philosophy to deliver exceptional results. For more information, visit or contact Forest Lake Endodontics, 1420 Lake Street S., Suite 200a, Forest Lake, MN 55025, 651-464-9888. View original content to download multimedia: SOURCE Forest Lake Endodontics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Biden EPA official challenges legality of DOE climate report
Biden EPA official challenges legality of DOE climate report

E&E News

time8 minutes ago

  • E&E News

Biden EPA official challenges legality of DOE climate report

The Biden EPA's research chief is formally requesting that the Department of Energy to correct a contrarian climate science report that is part of EPA's case for ending greenhouse gas regulation. Chris Frey, who led EPA's Office of Research and Development during the Biden administration, filed a 'request for correction' with DOE on Friday, citing 'legal and procedural irregularities' in how the report's authors were chosen and in the way they went about compiling and disseminating the assessment. Frey, who is now a professor at North Carolina State University, argued in his request for correction that the process violated four federal laws designed to ensure the integrity of federal science. Advertisement '[S]uch information is often perceived by the public and policymakers as authoritative and trustworthy,' he wrote. 'Consequently, rigorous adherence to information quality standards is not merely a bureaucratic formality but a fundamental requirement for maintaining public trust in government science and its capacity to provide objective, evidence-based guidance.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store